Common Contracts
2 similar Warrant Agreement contracts by I-Mab, Legend Biotech Corp
WARRANT TO PURCHASE ORDINARY SHARES of LEGEND BIOTECH CORPORATION Dated as of May 21, 2021Warrant Agreement • July 2nd, 2021 • Legend Biotech Corp • Pharmaceutical preparations • New York
THIS CERTIFIES THAT, for value received, LGN HOLDINGS LIMITED, or its registered assigns (the “Holder”), is entitled, subject to the provisions and upon the terms and conditions set forth herein, to purchase from Legend Biotech Corporation, a company incorporated under the laws of the Cayman Islands (the “Company”), ordinary shares of the Company, par value of US$0.0001 per share (the “Shares”), in the amounts, at such times and at the price per share set forth in Section 1. The term “Warrant” as used herein shall include this Warrant and any warrants delivered in substitution or exchange therefor as provided herein. This Warrant is issued in connection with the transactions described in the subscription agreement, dated as of May 13, 2021, by and among the Company and the Holder described therein (the “Purchase Agreement”). Capitalized terms used and not otherwise defined herein shall have the meanings set forth in the Purchase Agreement. The Holder is subject to certain restrictions
WARRANT TO PURCHASE ORDINARY SHARES of I-MAB Dated as of [●], 2020Warrant Agreement • December 1st, 2020 • I-Mab • Pharmaceutical preparations
THIS CERTIFIES THAT, for value received, [Name of Investor], or its registered assigns (the “Holder”), is entitled, subject to the provisions and upon the terms and conditions set forth herein, to purchase from I-Mab, a company incorporated under the laws of the Cayman Islands (the “Company”), ordinary shares of the Company, par value of US$0.0001 per share (the “Shares”), in the amounts, at such times and at the price per share set forth in Section 1. The term “Warrant” as used herein shall include this Warrant and any warrants delivered in substitution or exchange therefor as provided herein. This Warrant is issued in connection with the transactions described in the subscription agreement, dated as of September 1, 2020, by and among the Company and the Holder described therein (the “Purchase Agreement”). Capitalized terms used and not otherwise defined herein shall have the meanings set forth in the Purchase Agreement. The Holder is subject to certain restrictions set forth in the T
